Current and emerging strategies for engineered cell therapies: cancer immunotherapy

Cancer accounted for almost 10 million deaths in 2020, according to the World Health Organization, making this condition the cause of nearly one out of six deaths worldwide. Conventional treatments for cancer such as surgery, radiation and chemotherapy have been used for decades to help patients. However, issues such as aggressive treatments, long-term administration and side effects have led researchers to look elsewhere, within the realm of biologics and personalised treatments, at new cancer therapies.

Innovation in immunotherapy has enabled many cancer patients to benefit from cell therapy. However, there is still much work to be done in this area. Learn more in this ebook about the topics below:

Improving cellular therapies
Next-generation CAR T cells (Dr John Maher, Leucid Bio)
Allogeneic CAR T-cell therapy: the future of cancer care (Dr Devon, Shedlock Poseida Therapeutics)
The advantages of gamma-delta T-cell therapy (Dr Michael Leek, TC BioPharm)
Developing state-of-theart CAR T-cell therapy for cancer treatment (Dr Frank Neumann, Kite Pharma)
The next wave: going beyond CAR T cells with cell-based therapies (Dr Daniel Teper, Cytovia Therapeutics & Dr Chris Arendt, Takeda)

First Name

Last Name:

Email Address:

Organization:

Job Title:

Country:

State:

Postal Code:

Current and emerging strategies for engineered cell therapies: cancer immunotherapy

Section 3 H2 title

Section 3 column 1 H3

Section 3 column 2 H3

Section 3 Column 3 H3

Section 4 H2 title

Section 5 H2 title

Section 6 H2 title

Section 7 video H2 title

TGS challenge statement or question. [Edit under My Tokens]